Why Current Models Have Failed
The reason progress has been so slow is partly about the tools researchers use. For years, scientists studied ALS in mice and flat cell cultures grown in petri dishes. These models helped uncover some basic biology. But mice are not humans. And flat cell cultures miss the complex, three-dimensional structure of real nerve tissue.
Many promising drugs that worked in animals failed in human trials. The gap between the lab and the clinic has cost patients years — and lives.
Something Different Is Growing
But here's the twist: a new type of research tool called an organoid is changing what is possible.
Organoids are tiny, three-dimensional clusters of living cells that self-organize to resemble real organs or tissues. Researchers can grow them from a patient's own skin or blood cells by reprogramming those cells to behave like stem cells. From there, scientists can guide them to become nerve tissue — the same type destroyed in ALS.
Think of it like growing a very small model of a nerve circuit inside a dish. It is not a full spinal cord. But it behaves in many of the same ways.
These lab-grown nerve tissues — called spinal organoids or neuromuscular organoids — can replicate key features of ALS. Researchers have observed the same protein clumping, the same junction failures between nerves and muscles, and the same patterns of cell death seen in actual patients.
The connection between motor neurons (the nerve cells ALS destroys) and muscle cells is called the neuromuscular junction. Think of it as a plug and socket. In ALS, that connection breaks down. Organoid models now show this breakdown happening in human tissue for the first time — outside a living body.
This does not mean treatments grown from this research are available yet.
Researchers have also used these models to test potential drugs directly on human tissue. Early drug screening results show that some compounds can protect nerve cells in the dish. That is a meaningful step — but it is only a step.
The Study Behind the Science
This review, published in Frontiers in Medicine in April 2026, analyzed the full body of work on ALS organoid research to date. Scientists examined which protocols are most reliable, what disease features have been successfully recreated, and where the biggest gaps remain. No new treatments were tested. Instead, researchers mapped out the landscape of this emerging field to guide future work.
What They Found — And Why It Matters
The review found that organoid technology has already produced human-relevant insights that animal models could not. Specifically, the models captured genetic forms of ALS tied to mutations in genes like SOD1, TDP-43, and FUS — genes known to drive the disease in many patients.
Crucially, the models also revealed that non-nerve cells called glial cells play an active role in damaging motor neurons. This is significant. It means future treatments may need to target the whole disease environment — not just the motor neurons themselves.
That is not the full story, though.
The review was honest about the limits of this technology. Current organoid models do not perfectly replicate the entire spinal cord. They lack blood vessels, immune cells from the body, and the full mechanical environment of real tissue. These gaps could affect which drugs look promising in the dish.
Where This Fits in the Bigger Picture
Researchers see organoids as a bridge — not a destination. The goal is to use them to filter out drugs that will not work before spending millions of dollars on failed human trials. They could also help scientists understand why some people with ALS decline faster than others, and whether a treatment that works for one genetic type of ALS would work for another.
This kind of personalized research approach has already shown promise in cancer. ALS researchers hope to follow a similar path.
If you or someone you love has ALS, this research does not offer a new treatment today. But it represents a shift in how scientists study the disease — one that could lead to better options down the road.
The models are still being refined. Scientists are working to add vascular and immune components to make organoids even more realistic. Many research teams are also trying to standardize the methods so that results from one lab can be reliably compared to results from another.
The next phase of ALS organoid research will focus on making these models more consistent and more complete. Scientists want to use them for large-scale drug screens — testing hundreds or thousands of compounds at once to find those worth advancing to clinical trials. Some teams are already moving in this direction. If the models prove reliable enough, they could reshape how ALS drug development works — reducing the time and cost it takes to find treatments that genuinely help patients.
